Roxadustat (FG-4592): Correction of anemia in incident dialysis patients

Journal of the American Society of Nephrology

Volumn 27, Issue 4, 2016, Pages 1225-1233

  Besarab, Anatole ^a   Chernyavskaya, Elena ^b   Motylev, Igor ^c   Shutov, Evgeny ^d   Kumbar, Lalathaksha M ^e   Gurevich, Konstantin ^f   Chan, Daniel Tak Mao ^g   Leong, Robert ^a   Poole, Lona ^a   Zhong, Ming ^a   Saikali, Khalil G ^a   Franco, Marietta ^a   Hemmerich, Stefan ^a   Yu, Kin Hung Peony ^a   Neff, Thomas B ^a  

^a FIBROGEN INC   (United States)

^b City Clinical Hospital   (Russian Federation)

^c City Hospital 33   (Russian Federation)

^d City Clinical Hospital No36   (Russian Federation)

^e HENRY FORD HOSPITAL   (United States)

^f OOO Fresenius Medical Care   (Russian Federation)

^g UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; HEPCIDIN; IRON; ROXADUSTAT; TRANSFERRIN; FG-4592; GLYCINE; ISOQUINOLINE DERIVATIVE;

ADULT; ANEMIA; ARTICLE; CHOLESTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; IRON THERAPY; MALE; MEDICATION COMPLIANCE; OPEN STUDY; PATIENT COMPLIANCE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; MIDDLE AGED; PHASE 2 CLINICAL TRIAL;

ANEMIA; FEMALE; GLYCINE; HEPCIDINS; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; RENAL DIALYSIS;

EID: 85016925358     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/asn.2015030241     Document Type: Article

References (26)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296–1305, 2004
2. U.S. Renal Data System: 2013 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. Available at http://www.usrds.org/atlas.htm. Accessed October 1, 2014
3. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085–2098, 2006
4. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50: 471–530, 2007
5. Arbor Research Collaborative For Health. DOPPS Practice Monitor: 2013 Annual Report of the Dialysis Outcomes and Practice Patterns Study: Hemodialysis Data 1997-2012. Available at http://www.dopps.org/annualreport/
6. Ganz T: Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102: 783–788, 2003
7. Semenza GL: HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol (1985) 88: 1474–1480, 2000
8. Greijer AE, van der Groep P, Kemming D, Shvarts A, Semenza GL, Meijer GA, van de Wiel MA, Belien JA, van Diest PJ, van der Wall E: Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol 206: 291–304, 2005
9. Fan C, Iacobas DA, Zhou D, Chen Q, Lai JK, Gavrialov O, Haddad GG: Gene expression and phenotypic characterization of mouse heart after chronic constant or intermittent hypoxia. Physiol Genomics 22: 292–307, 2005
10. Peyssonnaux C, Nizet V, Johnson RS: Role of the hypoxia inducible factors HIF in iron metabolism. Cell Cycle 7: 28–32, 2008
11. Piperno A, Galimberti S, Mariani R, Pelucchi S, Ravasi G, Lombardi C, Bilo G, Revera M, Giuliano A, Faini A, Mainini V, Westerman M, Ganz T, Valsecchi MG, Mancia G, Parati G: Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: Data from the HIGHCARE project. ASH Annual Meeting Abstracts 117: 2953-2959, 2011
12. Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus S, Lee T, Leong R, Hemmerich S, Yu KHP, Neff TB: Randomized placebo-controlled dose-ranging and pharmaco-dynamics study of roxadustat (FG-4592) to treat anemia in non-dialysis chronic kidney disease (NDD-CKD) patients [published ahead of print August 3, 2015]. Nephrol Dial Transplant doi: 10.1093/ndt/gfv302
13. Johnson DW, Pollock CA, Macdougall IC: Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton) 12: 321–330, 2007
14. Macdougall IC, Cooper AC: Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 17[Suppl 11]: 39–43, 2002
15. Aranesp®: Medical officer clinical review (BLA: 99-1492/STN103951). 2001 BLA: 99-1492/STN103951. Available at: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm086019.pdf. Accessed on January 24, 2015
16. Coyne DW, Ling BN, Toto R, Lastname XY: Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant-human erythropoietin (r-HuEPO). J Am Soc Nephrol 11: A1380, 2000
17. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG: Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16: 3070–3080, 2005
18. Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason N, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM: Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int 87: 162–168, 2015
19. Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S; Dialysis Advisory Group of the American Society of Nephrology: Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol 26: 1238–1247, 2015
20. Amparo FC, Kamimura MA, Molnar MZ, Cuppari L, Lindholm B, Amodeo C, Carrero JJ, Cordeiro AC: Diagnostic validation and prognostic significance of the Malnutrition-Inflammation Score in nondialyzed chronic kidney disease patients. Nephrol Dial Transplant 30: 821–828, 2015
21. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 65: 1009–1016, 2004
22. Khan IH, Catto GR, Edward N, MacLeod AM: Death during the first 90 days of dialysis: a case control study. Am J Kidney Dis 25: 276–280, 1995
23. Wingard RL, Chan KE, Lazarus JM, Hakim RM: The “right” of passage: Surviving the first year of dialysis. Clin J Am Soc Nephrol 4[Suppl 1]: S114–S120, 2009
24. Eckardt KU, Gillespie IA, Kronenberg F, Richards S, Stenvinkel P, Anker SD, Wheeler DC, de Francisco AL, Marcelli D, Froissart M, Floege J; ARO Steering Committee: High cardiovascular event rates occur within the first weeks of starting hemodialysis [published online ahead of print April 29, 2015]. Kidney Int doi: 10.1038/ki.2015.117
25. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE: A randomized controlled study of iron, supplementation in patients treated with erythropoietin. Kidney Int 50: 1694–1699, 1996
26. Wingard RL, Parker RA, Ismail N, Hakim RM: Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 25: 433–439, 1995